Phase 3 Trial of Selpercatinib in Advanced RET-Mutant Medullary Thyroid Cancer. Hadoux J, Elisei R, Brose MS, Hoff AO, et al. N Engl J Med 2023 Oct 21. doi: 10.1056/NEJMoa2309719.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Hadoux J, Elisei R, Brose MS, Hoff AO, et al. Phase 3 Trial of Selpercatinib in Advanced RET-Mutant Medullary Thyroid Cancer. N Engl J Med 2023 Oct 21. doi: 10.1056/NEJMoa2309719.
PMID: 37870969